These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 33530328)

  • 1. CD137
    Ugolini A; Nuti M
    Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33530328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy.
    Liu G; Luo P
    Front Immunol; 2023; 14():1208788. PubMed ID: 37334375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.
    Sanchez-Paulete AR; Labiano S; Rodriguez-Ruiz ME; Azpilikueta A; Etxeberria I; Bolaños E; Lang V; Rodriguez M; Aznar MA; Jure-Kunkel M; Melero I
    Eur J Immunol; 2016 Mar; 46(3):513-22. PubMed ID: 26773716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis.
    Etxeberria I; Glez-Vaz J; Teijeira Á; Melero I
    ESMO Open; 2020 Jul; 4(Suppl 3):e000733. PubMed ID: 32611557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD137 and CD137 ligand constitutively coexpressed on human T and B leukemia cells signal proliferation and survival.
    Palma C; Binaschi M; Bigioni M; Maggi CA; Goso C
    Int J Cancer; 2004 Jan; 108(3):390-8. PubMed ID: 14648705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.
    Palazón A; Martínez-Forero I; Teijeira A; Morales-Kastresana A; Alfaro C; Sanmamed MF; Perez-Gracia JL; Peñuelas I; Hervás-Stubbs S; Rouzaut A; de Landázuri MO; Jure-Kunkel M; Aragonés J; Melero I
    Cancer Discov; 2012 Jul; 2(7):608-23. PubMed ID: 22719018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of CD137 on Hodgkin and Reed-Sternberg cells inhibits T-cell activation by eliminating CD137 ligand expression.
    Ho WT; Pang WL; Chong SM; Castella A; Al-Salam S; Tan TE; Moh MC; Koh LK; Gan SU; Cheng CK; Schwarz H
    Cancer Res; 2013 Jan; 73(2):652-61. PubMed ID: 23204227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.
    Mittler RS; Foell J; McCausland M; Strahotin S; Niu L; Bapat A; Hewes LB
    Immunol Res; 2004; 29(1-3):197-208. PubMed ID: 15181282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selection of Shared and Neoantigen-Reactive T Cells for Adoptive Cell Therapy Based on CD137 Separation.
    Seliktar-Ofir S; Merhavi-Shoham E; Itzhaki O; Yunger S; Markel G; Schachter J; Besser MJ
    Front Immunol; 2017; 8():1211. PubMed ID: 29067023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic vaccination with tumor cells that engage CD137.
    Hellstrom KE; Hellstrom I
    J Mol Med (Berl); 2003 Feb; 81(2):71-86. PubMed ID: 12601523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137.
    Li SY; Liu Y
    Clin Pharmacol; 2013 Sep; 5(Suppl 1):47-53. PubMed ID: 24052693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD137 Agonist Therapy Can Reprogram Regulatory T Cells into Cytotoxic CD4+ T Cells with Antitumor Activity.
    Akhmetzyanova I; Zelinskyy G; Littwitz-Salomon E; Malyshkina A; Dietze KK; Streeck H; Brandau S; Dittmer U
    J Immunol; 2016 Jan; 196(1):484-92. PubMed ID: 26608920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism.
    Labiano S; Palazón A; Bolaños E; Azpilikueta A; Sánchez-Paulete AR; Morales-Kastresana A; Quetglas JI; Perez-Gracia JL; Gúrpide A; Rodriguez-Ruiz M; Aznar MA; Jure-Kunkel M; Berraondo P; Melero I
    Oncoimmunology; 2016; 5(1):e1062967. PubMed ID: 26942078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation.
    Teijeira A; Labiano S; Garasa S; Etxeberria I; Santamaría E; Rouzaut A; Enamorado M; Azpilikueta A; Inoges S; Bolaños E; Aznar MA; Sánchez-Paulete AR; Sancho D; Melero I
    Cancer Immunol Res; 2018 Jul; 6(7):798-811. PubMed ID: 29678874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand.
    Kang SW; Lee SC; Park SH; Kim J; Kim HH; Lee HW; Seo SK; Kwon BS; Cho HR; Kwon B
    Cancer Res; 2017 Nov; 77(21):5989-6000. PubMed ID: 28923858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy with agonistic anti-CD137: two sides of a coin.
    Sun Y; Chen JH; Fu Y
    Cell Mol Immunol; 2004 Feb; 1(1):31-6. PubMed ID: 16212918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer.
    Gauttier V; Judor JP; Le Guen V; Cany J; Ferry N; Conchon S
    Int J Cancer; 2014 Dec; 135(12):2857-67. PubMed ID: 24789574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
    Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
    Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies.
    Melero I; Murillo O; Dubrot J; Hervás-Stubbs S; Perez-Gracia JL
    Trends Pharmacol Sci; 2008 Aug; 29(8):383-90. PubMed ID: 18599129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.
    Weigelin B; Bolaños E; Teijeira A; Martinez-Forero I; Labiano S; Azpilikueta A; Morales-Kastresana A; Quetglas JI; Wagena E; Sánchez-Paulete AR; Chen L; Friedl P; Melero I
    Proc Natl Acad Sci U S A; 2015 Jun; 112(24):7551-6. PubMed ID: 26034288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.